Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.01% | -6.39% | -11.51% | -28.10% | -21.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.73% | -1.18% | 13.26% | 6.91% | 6.98% |
| Operating Income | 4.28% | 1.18% | 1.34% | -366.06% | -6.98% |
| Income Before Tax | 54.94% | -3.77% | -4.45% | -549.82% | -141.94% |
| Income Tax Expenses | 150.97% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.10% | -3.77% | -6.09% | -549.82% | -128.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.10% | -3.77% | -6.09% | -549.82% | -128.06% |
| EBIT | 4.28% | 1.18% | 1.34% | -366.06% | -6.98% |
| EBITDA | 17.57% | 0.30% | 1.11% | -492.06% | -8.12% |
| EPS Basic | 50.53% | -0.72% | -3.64% | -445.83% | -65.61% |
| Normalized Basic EPS | 1.46% | -0.69% | -2.07% | -445.59% | 21.94% |
| EPS Diluted | 50.53% | -0.72% | -3.64% | -445.83% | -65.61% |
| Normalized Diluted EPS | 1.46% | -0.69% | -2.07% | -445.59% | 21.94% |
| Average Basic Shares Outstanding | 2.91% | 3.03% | 2.35% | 19.03% | 37.70% |
| Average Diluted Shares Outstanding | 2.91% | 3.03% | 2.35% | 19.03% | 37.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |